NCT02604537

Betamethasone Versus Ketorolac Injection for the Treatment of DeQuervains Tenosynovitis

Betamethason Versus Ketorolac Injection for the Treatment of DeQuervains Tenosynovitis

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 62 (actual)
• Sponsor: OrthoCarolina Research Institute, Inc. · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if corticosteroid injection modifies the natural course of de Quervain tendinopathy compared to a toradol injection.

Detailed description

If steroids are effective for Dequervain tenosynovitis because of their anti-inflammatory properties, then there is a reasonable and rational argument to be made for the local injection of NSAIDS (non-steroidal anti-inflammatory drugs) into the first dorsal extensor compartment. Ketorolac is an NSAID that has been proven efficacious in the treatment of another musculoskeletal condition. Moreover, compared to betamethasone (or other injectable corticosteroids), injection of ketorolac decreases the patient exposure to the potential side-effects of corticosteroids, especially that of elevation of blood sugar levels in diabetics.

Conditions

• DeQuervain Tendinopathy

Interventions

Type	Name	Description
DRUG	betamethasone	1 cc of 1% lidocaine (without epinephrine) plus 1 cc of 6 mg/ml betamethasone
DRUG	Ketorolac	1 cc of 1% lidocaine (without epinephrine) plus 1 cc of 30 mg/ml of ketorolac

Timeline

• Start date: 2015-10-15
• Primary completion: 2024-10-01
• Completion: 2024-10-30
• First posted: 2015-11-13
• Last updated: 2026-04-01

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study